{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T23:32:22Z","timestamp":1793748742664,"version":"4.6.1"},"reference-count":50,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2019,1,1]],"date-time":"2019-01-01T00:00:00Z","timestamp":1546300800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,1,1]],"date-time":"2019-01-01T00:00:00Z","timestamp":1546300800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Dermatologic Clinics"],"published-print":{"date-parts":[[2019,1]]},"DOI":"10.1016\/j.det.2018.08.003","type":"journal-article","created":{"date-parts":[[2018,11,19]],"date-time":"2018-11-19T19:31:24Z","timestamp":1542655884000},"page":"73-82","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":51,"title":["Updates in Melanoma"],"prefix":"10.1016","volume":"37","author":[{"given":"Elisabeth Hamelin","family":"Tracey","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alok","family":"Vij","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.det.2018.08.003_bib1","unstructured":"American Cancer Society. Statistics for 2016. Available at: www.cancer.org\/cancer\/melanoma-skin-cancer.html. Accessed June 1, 2018."},{"key":"10.1016\/j.det.2018.08.003_bib2","unstructured":"American Academy of Dermatology. Melanoma fact sheet. Available at: www.aad.org\/media\/stats\/conditions\/melanoma-faqs. Accessed June 1, 2018."},{"key":"10.1016\/j.det.2018.08.003_bib3","doi-asserted-by":"crossref","first-page":"1774","DOI":"10.1097\/00006534-200004050-00028","article-title":"Current therapy of cutaneous melanoma","volume":"105","author":"Wagner","year":"2001","journal-title":"Plast Reconstr Surg"},{"key":"10.1016\/j.det.2018.08.003_bib4","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1067\/mjd.2001.117044","article-title":"Guidelines\/outcomes committee. guidelines of care for primary cutaneous melanoma","volume":"45","author":"Sober","year":"2001","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.det.2018.08.003_bib5","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1067\/mjd.2000.104681","article-title":"Update on familial cancer syndromes and the skin","volume":"42","author":"Tsao","year":"2000","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.det.2018.08.003_bib6","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.ejca.2016.12.010","article-title":"The mitogen-activated protein kinase pathway in melanoma part I \u2014 Activation and primary resistance mechanisms to BRAF inhibition","volume":"73","author":"Amaral","year":"2017","journal-title":"Eur J Cancer"},{"issue":"6","key":"10.1016\/j.det.2018.08.003_bib7","first-page":"472","article-title":"Melanoma staging: evidence-based changes in the American Joint Committee on Cancer eighth edition cancer staging manual","volume":"67","author":"Gershenwald","year":"2017","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.det.2018.08.003_bib8","unstructured":"Skin Cancer Foundation. What is melanoma? Available at: www.skincancer.org\/skin-cancer-information\/melanoma. Accessed June 1, 2018."},{"key":"10.1016\/j.det.2018.08.003_bib9","unstructured":"Clinical practice guidelines: melanoma. National Comprehensive Cancer Network. Available at: www.nccn.org\/professionals\/physician_gls\/PDF\/melanoma.pdf. Accessed September 10, 2018."},{"key":"10.1016\/j.det.2018.08.003_bib10","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1016\/S0190-9622(96)90017-1","article-title":"Favorable prognostic factors in recurrent and metastatic melanoma","volume":"34","author":"Buzzell","year":"1996","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.det.2018.08.003_bib11","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/S0094-1298(20)32737-1","article-title":"Lymphatic mapping and sentinel lymph node biopsies","volume":"27","author":"Ali-Salaam","year":"2000","journal-title":"Clin Plast Surg"},{"issue":"4","key":"10.1016\/j.det.2018.08.003_bib12","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1245\/s10434-018-6348-2","article-title":"Predictors for use of sentinel node biopsy and the association with improved survival in melanoma patients who have nodal staging","volume":"25","author":"Murtha","year":"2018","journal-title":"Ann Surg Oncol"},{"issue":"7","key":"10.1016\/j.det.2018.08.003_bib13","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1056\/NEJMoa1310460","article-title":"Final trial report of sentinel-node biopsy versus nodal observation in melanoma","volume":"370","author":"Morton","year":"2014","journal-title":"N\u00a0Engl J Med"},{"issue":"5","key":"10.1016\/j.det.2018.08.003_bib14","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1016\/j.jaad.2018.01.030","article-title":"Prognostic value of sentinel lymph node biopsy according to Breslow thickness for cutaneous melanoma","volume":"78","author":"Stiegel","year":"2018","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.det.2018.08.003_bib15","series-title":"Andrews\u2019 diseases of the skin","first-page":"881","article-title":"Melanocytic nevi and neoplasms","author":"Odom","year":"2000"},{"issue":"4","key":"10.1016\/j.det.2018.08.003_bib16","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1016\/0190-9622(95)91284-3","article-title":"Melanocytic nevi, dysplastic nevi, and malignant melanoma in children from melanoma-prone families","volume":"33","author":"Novakovic","year":"1995","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.det.2018.08.003_bib17","doi-asserted-by":"crossref","first-page":"458","DOI":"10.7326\/0003-4819-102-4-458","article-title":"High risk of malignant melanoma in melanoma-prone families with dysplastic nevi","volume":"102","author":"Greene","year":"1985","journal-title":"Ann Intern Med"},{"issue":"23","key":"10.1016\/j.det.2018.08.003_bib18","doi-asserted-by":"crossref","first-page":"2211","DOI":"10.1056\/NEJMoa1613210","article-title":"Completion dissection or observation for sentinel-node metastasis in melanoma","volume":"376","author":"Faries","year":"2017","journal-title":"N\u00a0Engl J Med"},{"issue":"6","key":"10.1016\/j.det.2018.08.003_bib19","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1016\/S1470-2045(16)00141-8","article-title":"Complete lymph node dissection versus no dissection in patients with sentinel lymph node biopsy positive melanoma (DeCOG-SLT): a multicentre, randomised, phase 3 trial","volume":"17","author":"Leiter","year":"2016","journal-title":"Lancet"},{"issue":"10","key":"10.1016\/j.det.2018.08.003_bib20","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1200\/JCO.2015.63.3776","article-title":"Final results of the Sunbelt Melanoma Trial: a multi-institutional prospective randomized phase III study evaluating the role of adjuvant high-dose interferon alfa-2b and completion lymph node dissection for patients staged by sentinel lymph node biopsy","volume":"34","author":"McMasters","year":"2016","journal-title":"J\u00a0Clin Oncol"},{"issue":"4","key":"10.1016\/j.det.2018.08.003_bib21","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1200\/JCO.2017.75.7724","article-title":"Sentinel lymph node biopsy and management of regional lymph nodes in melanoma: American Society of Clinical Oncology and Society of Surgical Oncology Clinical Practice Guideline Update","volume":"36","author":"Wong","year":"2018","journal-title":"J\u00a0Clin Oncol"},{"issue":"2","key":"10.1016\/j.det.2018.08.003_bib22","first-page":"196","article-title":"Impact of gene expression profiling on decision-making in clinically node negative melanoma patients after surgical staging","volume":"17","author":"Schuitevoerder","year":"2018","journal-title":"J\u00a0Drugs Dermatol"},{"issue":"1","key":"10.1016\/j.det.2018.08.003_bib23","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1158\/1078-0432.CCR-13-3316","article-title":"Development of a prognostic genetic signature to predict the metastatic risk associated with cutaneous melanoma","volume":"21","author":"Gerami","year":"2015","journal-title":"Clin Cancer Res"},{"issue":"1","key":"10.1016\/j.det.2018.08.003_bib24","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1186\/s12885-018-4016-3","article-title":"Performance of a prognostic 31-gene expression profile in an independent cohort of 523 cutaneous melanoma patients","volume":"18","author":"Zager","year":"2018","journal-title":"BMC Cancer"},{"issue":"5","key":"10.1016\/j.det.2018.08.003_bib25","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1016\/j.jaad.2016.11.051","article-title":"Identification of high-risk cutaneous melanoma tumors is improved when combining the online American Joint Committee on Cancer Individualized Melanoma Patient Outcome Prediction Tool with a 31-gene expression profile-based classification","volume":"76","author":"Ferris","year":"2017","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"1","key":"10.1016\/j.det.2018.08.003_bib26","doi-asserted-by":"crossref","DOI":"10.1093\/jnci\/djv294","article-title":"Melanoma thickness and survival trends in the United States, 1989 to 2009","volume":"108","author":"Shaikh","year":"2015","journal-title":"J\u00a0Natl Cancer Inst"},{"issue":"5","key":"10.1016\/j.det.2018.08.003_bib27","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1016\/j.jaad.2017.02.045","article-title":"Commentary: the quest for an improved risk stratification tool for patients with melanoma","volume":"76","author":"Ming","year":"2017","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"5","key":"10.1016\/j.det.2018.08.003_bib28","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1016\/j.jaad.2015.01.009","article-title":"Gene expression profiling for molecular staging of cutaneous melanoma in patients undergoing sentinel lymph node biopsy","volume":"72","author":"Gerami","year":"2015","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.det.2018.08.003_bib29","doi-asserted-by":"crossref","first-page":"3807","DOI":"10.1002\/cncr.29050","article-title":"Clinical and prognostic factors for melanoma of the skin using SEER registries: collaborative stage data collection system, version 1 and version 2","volume":"120","author":"Kosary","year":"2014","journal-title":"Cancer"},{"key":"10.1016\/j.det.2018.08.003_bib30","doi-asserted-by":"crossref","DOI":"10.1097\/DSS.0000000000001588","article-title":"Estimation of prognosis in invasive cutaneous melanoma: an independent study of the accuracy of a gene expression profile test","author":"Greenhaw","year":"2018","journal-title":"Dermatol Surg"},{"issue":"1","key":"10.1016\/j.det.2018.08.003_bib31","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1186\/s13045-017-0520-1","article-title":"Interim analysis of survival in a prospective, multi-center registry cohort of cutaneous melanoma tested with a prognostic 31-gene expression profile test","volume":"10","author":"Hsueh","year":"2017","journal-title":"J\u00a0Hematol Oncol"},{"issue":"9","key":"10.1016\/j.det.2018.08.003_bib32","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1080\/03007995.2016.1192997","article-title":"Clinical impact of a 31-gene expression profile test for cutaneous melanoma in 156 prospectively and consecutively tested patients","volume":"32","author":"Berger","year":"2016","journal-title":"Curr Med Res Opin"},{"issue":"5","key":"10.1016\/j.det.2018.08.003_bib33","first-page":"428","article-title":"Impact of a 31-gene expression profiling test for cutaneous melanoma on dermatologists' clinical management decisions","volume":"16","author":"Farberg","year":"2017","journal-title":"J\u00a0Drugs Dermatol"},{"issue":"5","key":"10.1016\/j.det.2018.08.003_bib34","first-page":"544","article-title":"Factors affecting dermatologists' use of a 31-gene expression profiling test as an adjunct for predicting metastatic risk in cutaneous melanoma","volume":"17","author":"Svoboda","year":"2018","journal-title":"J\u00a0Drugs Dermatol"},{"issue":"4","key":"10.1016\/j.det.2018.08.003_bib35","first-page":"346","article-title":"Current and future roles of targeted therapy and immunotherapy in advanced melanoma","volume":"20","author":"Olszanski","year":"2014","journal-title":"J\u00a0Manag Care Spec Pharm"},{"issue":"26","key":"10.1016\/j.det.2018.08.003_bib36","doi-asserted-by":"crossref","first-page":"2507","DOI":"10.1056\/NEJMoa1103782","article-title":"Improved survival with vemurafenib in melanoma with BRAF V600E mutation","volume":"364","author":"Chapman","year":"2011","journal-title":"N\u00a0Engl J Med"},{"issue":"9839","key":"10.1016\/j.det.2018.08.003_bib37","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/S0140-6736(12)60868-X","article-title":"Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial","volume":"380","author":"Hauschild","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.det.2018.08.003_bib38","first-page":"2251","article-title":"Trametinib: a MEK inhibitor for management of metastatic melanoma","volume":"8","author":"Lugowska","year":"2015","journal-title":"Onco Targets Ther"},{"issue":"9","key":"10.1016\/j.det.2018.08.003_bib39","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1016\/S1470-2045(14)70301-8","article-title":"Combination of vemurafenib and cobimetinib in patients with advanced BRAF(V600)-mutated melanoma: a phase 1b study","volume":"15","author":"Ribas","year":"2014","journal-title":"Lancet Oncol"},{"issue":"19","key":"10.1016\/j.det.2018.08.003_bib40","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1056\/NEJMoa1708539","article-title":"Adjuvant dabrafenib plus trametinib in stage III BRAF-mutated melanoma","volume":"377","author":"Long","year":"2017","journal-title":"N\u00a0Engl J Med"},{"issue":"9","key":"10.1016\/j.det.2018.08.003_bib41","doi-asserted-by":"crossref","first-page":"2005","DOI":"10.1002\/cncr.21834","article-title":"Multicenter phase II trial of high-dose imatinib mesylate in metastatic melanoma: significant toxicity with no clinical efficacy","volume":"106","author":"Wyman","year":"2006","journal-title":"Cancer"},{"issue":"8","key":"10.1016\/j.det.2018.08.003_bib42","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1038\/sj.bjc.6602529","article-title":"Lack of clinical efficacy of imatinib in metastatic melanoma","volume":"92","author":"Ugurel","year":"2005","journal-title":"Br J Cancer"},{"issue":"6165","key":"10.1016\/j.det.2018.08.003_bib43","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1126\/science.342.6165.1432","article-title":"Breakthrough of the year 2013: cancer immunotherapy","volume":"342","author":"Couzin-Frankel","year":"2013","journal-title":"Science"},{"issue":"26","key":"10.1016\/j.det.2018.08.003_bib44","doi-asserted-by":"crossref","first-page":"2517","DOI":"10.1056\/NEJMoa1104621","article-title":"Ipilimumab plus dacarbazine for previously untreated metastatic melanoma","volume":"364","author":"Robert","year":"2011","journal-title":"N\u00a0Engl J Med"},{"issue":"10","key":"10.1016\/j.det.2018.08.003_bib45","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1200\/JCO.2014.56.6018","article-title":"Five-year survival rates for treatment-naive patients with advanced melanoma who received ipilimumab plus dacarbazine in a phase III trial","volume":"33","author":"Maio","year":"2015","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.det.2018.08.003_bib46","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.ejca.2017.07.022","article-title":"Final analysis of a randomised trial comparing pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory advanced melanoma","volume":"86","author":"Hamid","year":"2017","journal-title":"Eur J Cancer"},{"issue":"105","key":"10.1016\/j.det.2018.08.003_bib47","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1016\/S0140-6736(17)31601-X","article-title":"Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006)","volume":"390","author":"Schachter","year":"2017","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.det.2018.08.003_bib48","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1056\/NEJMoa1412082","article-title":"Nivolumab in previously untreated melanoma without BRAF mutation","volume":"372","author":"Robert","year":"2015","journal-title":"N\u00a0Engl J Med"},{"issue":"4","key":"10.1016\/j.det.2018.08.003_bib49","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/S1470-2045(15)70076-8","article-title":"Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial","volume":"16","author":"Weber","year":"2015","journal-title":"Lancet Oncol"},{"issue":"1","key":"10.1016\/j.det.2018.08.003_bib50","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1056\/NEJMoa1504030","article-title":"Combined nivolumab and ipilimumab or monotherapy in untreated melanoma","volume":"373","author":"Larkin","year":"2015","journal-title":"N\u00a0Engl J Med"}],"container-title":["Dermatologic Clinics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0733863518311070?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0733863518311070?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T10:41:52Z","timestamp":1760006512000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0733863518311070"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1]]},"references-count":50,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,1]]}},"alternative-id":["S0733863518311070"],"URL":"https:\/\/doi.org\/10.1016\/j.det.2018.08.003","relation":{},"ISSN":["0733-8635"],"issn-type":[{"value":"0733-8635","type":"print"}],"subject":[],"published":{"date-parts":[[2019,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Updates in Melanoma","name":"articletitle","label":"Article Title"},{"value":"Dermatologic Clinics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.det.2018.08.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}